|
OBJECTIVE: To evaluate the cost utility of imatinib compared with
interferon (IFN)-alpha or hydroxycarbamide (hydroxyurea) for first-line
treatment of chronic myeloid leukaemia. DESIGN AND SETTING: A cost-utility
(Markov) model within the setting of the UK NHS and viewed from a health system
perspective was adopted. Transition probabilities and relative risks were
estimated from published literature.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML Yahoo! Groups Links
|
